LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

Search

Celldex Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

26.77 1.36

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

26.49

Max

26.8

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-10M

-67M

Pelnas, tenkantis vienai akcijai

-1.01

Pelno marža

-7,753.425

Darbuotojai

186

EBITDA

-3.2M

-66M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+104.07% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

244M

1.7B

Ankstesnė atidarymo kaina

25.41

Ankstesnė uždarymo kaina

26.77

Naujienos nuotaikos

By Acuity

50%

50%

168 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-27 16:49; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

2025-11-27 15:32; UTC

Įsigijimai, susijungimai, perėmimai

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

2025-11-27 23:50; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

2025-11-27 23:50; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-11-27 16:05; UTC

Rinkos pokalbiai

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

2025-11-27 16:04; UTC

Rinkos pokalbiai

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

2025-11-27 15:54; UTC

Įsigijimai, susijungimai, perėmimai

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

2025-11-27 15:44; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse: No Certainty Talks Will Result in Transaction

2025-11-27 15:43; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

2025-11-27 15:42; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

2025-11-27 15:41; UTC

Įsigijimai, susijungimai, perėmimai

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

2025-11-27 15:11; UTC

Rinkos pokalbiai

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

2025-11-27 14:26; UTC

Rinkos pokalbiai

Hermes' Outperformance Gap Could Narrow -- Market Talk

2025-11-27 14:11; UTC

Rinkos pokalbiai

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

2025-11-27 14:11; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-11-27 13:35; UTC

Rinkos pokalbiai

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

2025-11-27 13:33; UTC

Rinkos pokalbiai

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

2025-11-27 13:22; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-11-27 13:22; UTC

Rinkos pokalbiai

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

2025-11-27 13:17; UTC

Rinkos pokalbiai

LVMH Should Be Able to Recover Next Year -- Market Talk

2025-11-27 11:13; UTC

Rinkos pokalbiai

European Gas Prices Come Under Pressure -- Market Talk

2025-11-27 11:07; UTC

Uždarbis

Genting: Positive About Prospects Over Longer Term

2025-11-27 11:06; UTC

Uždarbis

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

2025-11-27 11:04; UTC

Uždarbis

Genting: International Travel Demand Expected to Remain Resilient

2025-11-27 11:04; UTC

Uždarbis

Genting: Global Growth Expected to Remain Subdued

2025-11-27 11:04; UTC

Uždarbis

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

2025-11-27 10:59; UTC

Uždarbis

Genting Bhd 3Q Net Profit Fell 86% on Year

2025-11-27 10:58; UTC

Uždarbis

Genting Bhd 3Q Rev Rose 14% on Year

2025-11-27 10:56; UTC

Uždarbis

Genting Bhd 3Q Net MYR30.3M

2025-11-27 10:56; UTC

Uždarbis

Genting Bhd 3Q EPS MYR0.0079

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

104.07% į viršų

12 mėnesių prognozė

Vidutinis 54.67 USD  104.07%

Aukščiausias 90 USD

Žemiausias 21 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

9

Pirkti

0

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

168 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat